IPSEN (OTCMKTS:IPSEY) Short Interest Down 97.6% in September

Key Points

• IPSEN experienced a dramatic 97.6% decline in short interest in September, dropping from 4,200 shares to just 100 shares.
• The stock price rose by 3.7%, reaching $33.20 during trading hours, with a trading volume of 264 shares.
• IPSEN's current days-to-cover ratio is 0.2 days, based on an average trading volume of 500 shares.

IPSEN (OTCMKTS:IPSEY - ) saw a significant decline in short interest during the month of September. As of September 15th, there was short interest totaling 100 shares, a decline of 97.6% from the August 31st total of 4,200 shares. Based on an average trading volume of 500 shares, the days-to-cover ratio is currently 0.2 days. Based on an average trading volume of 500 shares, the days-to-cover ratio is currently 0.2 days.

IPSEN Trading Up 3.7%

Shares of OTCMKTS:IPSEY traded up $1.18 during trading hours on Tuesday, reaching $33.20. The stock had a trading volume of 264 shares, compared to its average volume of 363. IPSEN has a 1 year low of $25.11 and a 1 year high of $35.08. The firm's 50 day moving average is $33.16 and its 200-day moving average is $30.54.

IPSEN Company Profile

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.